Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to inform the development of a scalable and practical delivery and healthcare provider training model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (TRD).

The first phase of the collaboration comprises an in-depth information exchange on the COMP360 psilocybin treatment delivery model. Together, Compass and Journey Clinical will work to better understand the patient care experience, depression patient pathways and care reimbursement processes, and explore innovative care pathways for TRD patients, should COMP360 psilocybin treatment be approved. They will conduct research into therapist training, support, and education, and exchange information on treatment settings for psychedelic therapies.

Journey Clinical has built the necessary infrastructure to support broad access to new psychedelic treatments for mental health conditions, if and when approved. Their collaborative care model connects a dedicated medical team, licensed psychotherapists, and patients, supporting the delivery of psychedelic treatments responsibly and at scale, starting with ketamine-assisted psychotherapy. They have a network of over 2,000 therapists, an in-house model of therapist peer support and mentorship, and are partnered with leading therapist training providers.

“We are thrilled to be a research collaboration partner for Compass and to contribute towards how COMP360 psilocybin treatment may be delivered to patients across the US, if it receives regulatory approval,” said Jonathan Sabbagh, co-founder and CEO of Journey Clinical. “This collaboration with Compass is closely aligned with Journey Clinical’s aim to support the millions of people in the US living with mental illness to access psychedelic treatments safely and effectively.”

Compass has previously announced research collaboration agreements with Greenbrook TMS, a leading provider of interventional psychiatric treatments such as transcranial magnetic stimulation, and Hackensack Meridian Health, a leading not-for-profit health care organization and the largest, most comprehensive and truly integrated network in New Jersey, addressing the full continuum of care for people living with TRD.